What this Trial Is About

Researchers are studying visceral leishmaniasis (VL), a disease caused by protozoan parasites from the genus Leishmania, which affects humans and animals worldwide. VL is notable for causing serious symptoms such as fever, weight loss, and enlargement of the spleen and liver. This research focuses on understanding the epidemiology of VL in the Emilia-Romagna region, especially noting an increase in cases in the Province of Bologna since 2012. The goal is to develop guidelines to improve diagnosis and treatment, reduce delays in diagnosis, and explore new ways to control disease transmission. The study is designed as a retrospective and prospective observational investigation, collecting data on patients diagnosed with VL from March 2020 to February 2025. It assesses the socio-demographic and clinical features of these patients. Diagnosis methods include serological tests, molecular biology tests like RT-PCR, microscopic examination, and culture techniques to confirm infection. The research does not involve specific drug or treatment interventions but focuses on data collection and observation to better understand the disease's characteristics. Participants diagnosed with VL will have their medical and laboratory information analyzed to describe the disease's epidemiology and clinical profile. Researchers will monitor the progression and treatment outcomes to identify factors that may affect disease control and patient recovery. This study will follow patients over five years, aiming to improve therapeutic results and provide a scientific basis for future guidelines and strategies to reduce transmission of visceral leishmaniasis in the region.

Visceral Leishmaniasis in Emilia-Romagna (Leishmania-2019)